NCT02427451View on ClinicalTrials.gov

Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 3, 2015

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic Leukemia

Interventions

DRUG

Bcl-2 Inhibitor GDC-0199

Given PO

BIOLOGICAL

Obinutuzumab

Given IV

DRUG

Ibrutinib

Given PO

OTHER

Pharmacological Study

Correlative studies

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors

lead

Kerry Rogers

OTHER

NCT02427451 - Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter